NCT01545882View on ClinicalTrials.gov

A Phase II Study of Degarelix in the Management of Non-Metastatic Hormone-Refractory Prostate Cancer

PHASE2TerminatedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

May 31, 2011

Primary Completion Date

October 31, 2011

Study Completion Date

July 31, 2013

Conditions
Prostatic Neoplasms
Interventions
DRUG

Degarelix

Treatment will consist of a starting dose of 240mg injected subcutaneously (s.c) and monthly s.c. maintenance doses of 80mg for a total duration of 6 months.

Trial Locations (3)

N6A 4L6

London Regional Cancer Centre, London

K1H8L6

Ottawa Hospital Cancer Centre, Ottawa

M5G 2M9

Princess Margeret Hospital, Toronto

Sponsors
All Listed Sponsors
lead

Ottawa Hospital Research Institute

OTHER